INTRODUCTION
Interferons are naturally occurring cytokines involved in host defenses against a variety of infectious agents and in¯ammation. 1 Interferons are clinically useful in some malignant, viral, immmunological, angiogenic, in¯ammatory and ®brotic diseases. 2 Currently, interferons are also the ®rst line therapy for chronic hepatitis C virus infection. 3 Most studies of the effects of interferons in patients with chronic hepatitis C have used recombinant-derived (alpha 2a or 2b) or naturally produced (lymphoblastoid) interferon-a, 3, 4 and some authors have found changes in lipid and lipoprotein composition during interferon-a therapy. The most notable changes have been an increase in total and very low density lipoprotein (VLDL) triglycerides and a decrease in high density lipoprotein (HDL) cholesterol. 5, 6 In addition, severe hypertriglyceridaemia and chylomicronaemia have been reported in a few patients treated with interferon-a. 6±10 In such patients, pretreatment triglyceride levels were usually elevated. 6, 7 Interferon-b, a naturally produced cytokine derived from epithelial cells and ®broblasts is also marketed for the treatment of chronic hepatitis C in several European countries and Japan. 3 Recently, interferon-b has also shown ef®cacy in the therapy of multiple sclerosis. 11 
SUMMARY
Background: Interferon therapy has been shown to induce lipid abnormalities. Aim: We assessed the effects of interferon-b on the lipoprotein pro®le and post-heparin lipase activities in 26 normolipaemic patients with chronic hepatitis C. Methods: Interferon-b was administered subcutaneously at doses of 6´10 6 U (units) three times a week, over 6 months, and lipoproteins and post-heparin lipases were measured at baseline and at the end of therapy. Results: Plasma triglycerides increased by 21% due to preferential enrichment in those contained in the very low density lipoprotein (VLDL) and low density lipoprotein (LDL) fractions. The concentration of cholesterol decreased slightly in the high density lipoprotein (HDL) subfractions. Lipoprotein lipase, but not hepatic lipase activity decreased by a 36%, and this change showed a signi®cant negative correlation with changes in plasma triglycerides. Five patients (19.5%) responded to interferon-b therapy. The lipoprotein pro®le was no different between responders and non-responders to therapy. Conclusions: Interferon-b treatment in normolipaemic patients with chronic hepatitis C induced moderate disturbances in plasma lipoproteins, associated with inhibition of lipoprotein lipase activity.
Although lipid disturbances have been noted in association with interferon-b therapy, neither the lipoprotein pro®le nor the mechanism whereby interferon-b causes such changes have been fully investigated. 12, 13 In the present study we prospectively evaluated the effects of interferon-b therapy on lipoprotein pattern and post-heparin lipase activities in normolipaemic patients with chronic hepatitis C, and examined the relationship of these effects with the response to treatment.
MATERIALS AND METHODS
The study was designed and conducted at the Liver Unit, University Hospital of Ma Âlaga (Spain) and was supported by Department of Medicine. It was not a part of a sponsored study.
Patients
A total of 26 consecutive patients with chronic hepatitis C were prospectively included in the study between April and June 1996. To be included, a patient had to have hepatitis C virus antibodies detectable by ELISA (Ortho Diagnostics, Neckargemu È n, Germany), 1 RNA positivity by the polymerase chain reaction (Amplicor, Hoffmann-La Roche, Basel, Switzerland), and biopsyproven chronic hepatitis within 6 months prior to the study. Exclusion criteria were: positive serology for hepatitis B virus infection or human immunode®ciency virus; cirrhosis; marked obesity (body mass index > 30); diabetes; hyperlipemia (cholesterol > 240 mg/dL; triglycerides > 150 mg/dL), or any other disease known to alter the lipid pro®le; history of alcohol use; or therapy with drugs known to in¯uence plasma lipid or lipoproteins. Patients were instructed not to alter their dietary habits during the course of the study.
Patients received interferon-b (Frone, Serono, Madrid, Spain) subcutaneously at a dose of 6´10 6 U, three times a week over a 6-month period. The objective of this study, speci®cally designed to evaluate lipid changes during interferon-b therapy, was thoroughly explained to all participants, who signed an informed consent.
Assessment of ef®cacy
Parameters monitored in all patients at baseline and at the end of therapy were: body mass index, serum glucose, aspartate aminotransferase, alanine aminotransferase, bilirubin, albumin and prothrombin activity.
The response to treatment was de®ned according to the criteria of the National Institutes of Health Consensus Development Conference on Hepatitis C as normal serum alanine aminotransferase concentrations and undetectable serum hepatitis C virus RNA levels at the end of therapy. 14 Liver biopsy specimens obtained before treatment and at the end of the follow-up period were interpreted by a single pathologist in a blinded fashion. The degree of hepatic in¯ammation and ®brosis was scored with the Knodell histological activity index. 15 In¯ammation and ®brosis scores were evaluated separately.
Lipoprotein analysis
Lipid and lipoproteins were evaluated at baseline and at the end of therapy. Fasting blood specimens were collected by venipuncture into tubes containing sodium EDTA, and were centrifuged at 1500 g for 30 min at 4°C. Total cholesterol, triglycerides and phospholipids in plasma, and lipoprotein fractions were assayed enzimatically in a Cobas MIRA autoanalyser (Hoffmann-La Roche). Very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high ensity lipoprotein subfractions (HDL 2 and HDL 3 ) were isolated by sequential¯otation in a preparative ultracentrifuge (Beckman L8±55 M, Palo Alto, California, USA) according to the method of Havel et al., 2 using a 50.3 Ti Beckman rotor. 16 With the addition of a KBr + NaCl mixture, each lipoprotein was fractionated at the following densities: VLDL, d < 1.006 g/mL; LDL, d 1.006± 1.063 g/mL; HDL 2 , d 1.063±1.125 g/mL; and HDL 3 , d 1.125±1.210 g/mL.
Activities of lipoprotein lipase and hepatic lipase in postheparin plasma
Lipolytic enzymes are anchored to the vessel wall, but can be removed by infusing molecules with high af®nity to lipases 3 , such as heparin. Lipolytic activities should therefore be assayed in post-heparin plasma. Plasma samples were obtained 10 min after the intravenous injection of heparin at a dose of 50 UI/kg body weight, and stored at )70°C until assay. The activities of lipoprotein lipase and hepatic lipase were measured by a radioisotopic method using H3-Triolein as a substrate, emulsi®ed by sonication with Triton X-100 (Branson 250, Danbury, Connecticut, USA). Post-heparin lipase activity was measured as the difference in salt sensitiv-ity: the enzymatic activity of lipoprotein lipase is inhibited by high salt concentrations, whereas hepatic lipase is active in 1 M NaCl. 17 In addition, apolipoprotein (Apo) C-II is required as a co-factor for maximal lipoprotein lipase activity, whereas hepatic lipase has no co-factor requirements. To measure post-heparin lipase activities, each assay was performed in triplicate tubes, including a no-plasma blank, with plasma, and with plasma plus 1 M NaCl. All tubes (refrigerated on ice) contained 200 lL of substrate and 10 lL of post-heparin plasma. For the tubes with salt (hepatic lipase activity), 50 lL 5 M NaCl was added. For tubes without a high salt concentration, 50 lL of human plasma with Apo-CII (0.1 M NaCl; total activity of post-heparin plasma) was added. The tubes were incubated at 37°C for 1 h and the reaction was then stopped by adding 3 mL of methanol/chloroform/heptane (1.4:1.25:1.0; v/v/vol) with 1 mL carbonate/ borate buffer, pH 10.5. Fatty acids were extracted by the method of Belfrage and Vaughan. 18 After vortexing, the samples were centrifuged at 1500 g 4 for 15 min at 4°C. One millilitre of the top fraction (aqueous phase) was then removed and radioactivity was determined. Lipoprotein lipase activity was determined by subtracting hepatic lipase activity (samples plus 1 M NaCl) from total Phepatic lipase activity. Paired samples (i.e. before and after treatment) were assayed in the same batch. Whitin-batch coef®cient of variation for total postheparin lipase activity and hepatic lipase activity were 2.3% and 9.4%, respectively. All enzyme activities are expressed as micromoles of free fatty acids per hour per millilitre of plasma.
Statistical analysis
All values are expressed as the mean s.d. Statistical analysis was performed with statistical software (SPSS/ PC+, SPSS Inc, Chicago, IL) on a personal computer. Student's paired t-test was used for comparisons between values before and after treatment with interferon-b, when the means of variables were distributed normally. For lipoproteins and post-heparin lipase activities, pairwise comparisons were tried. However, the Wilcoxon signed ranks test was used because the values did not show a normal distribution. For other comparisons we used the non-parametric Mann±Whit-ney test. Data were analysed by calculating Pearson's correlation coef®cient.
RESULTS
The characteristics of the patients at the start of interferon-b therapy are shown in Table 1 . No patient had any serious or potentially life-threatening complications, and all patients completed the trial, receiving the same total dose of interferon-b (432´10 6 U). No signi®cant changes were observed, after interferon-b treatment, in body mass index, leucocyte and platelet count or liver function as measured by bilirubin, albumin and prothrombin time. A slight increase in haemoglobin levels and a decrease in serum glucose (both within the normal range) at the end of therapy was noted (median values: basal 15 1.1 g/dL; 6 months 15.5 1.2 g/dL, P < 0.01; basal 106.3 19.1 mg/dL; 6 months 102.6 19.5 mg/dL, P < 0.05, respectively). Table 2 shows the effect of interferon-b therapy on the concentration of cholesterol, triglycerides and phospholipids in plasma and on the lipoprotein fractions. After 6 months of treatment, mean plasma triglyceride level had increased by 21%, whereas no changes were noted in the plasma concentration of total cholesterol and phospholipids. All lipoprotein fractions were enriched in triglycerides, but the increases were statistically significant only in the VLDL and LDL fractions. In contrast there was a slight (but not statistically signi®cant) decrease in HDL cholesterol due to that contained in both subfractions HDL 2 and HDL 3 . Post-heparin lipase activities measured in the 26 patients before and after interferon-b treatment are shown in Figure 1 . The activity of post-heparin lipase showed a tendency to decrease as a result of interferon-b therapy (median values: basal 5.7 4.1 lmol; 6 months 5.13.9 lmol free fatty acids/mL per hour) due to a signi®cant decrease in lipoprotein lipase activity (median values: basal 1.9 1.3 lmol; 6 months 1.2 1.2 lmol free fatty acids/mL per hour, P < 0.001). This decrease was noted in 24 of the 26 patients (88.4%). The mean percentage decrease in lipoprotein lipase activity was 36%. In contrast, hepatic lipase activity did not change with interferon-b treatment (median values: basal 3.8 3.2 lmol; 6 months 3.9 3.4 lmol free fatty acids/mL per hour).
Five patients (19.5%) responded to interferon-b therapy. Lipid and lipoprotein changes were no different between responders and non-responders. However, in the whole group, alanine aminotransferase and aspartate aminotransferase correlated with lipoprotein lipase activity at the end of treatment (r 0.569, P < 0.01 for both).
Thirteen patients underwent a second liver biopsy 12 months after the end of the trial. Although there was only one responder in this group, the histological activity index improved signi®cantly after interferon-b ; second biopsy 7.2 3.3 6 , P < 0.05). Histological improvement was exclusively due to a decrease in the in¯ammatory scores from 7.6 2. ; second biopsy 2.1 1.1
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). Table 3 shows simple correlation coef®cients for the changes in lipoprotein lipase, hepatic lipase and postheparin lipase activities and those of serum lipids and lipoproteins during 6 months of treatment with interferon-b. The change (D) in post-heparin lipase and lipoprotein lipase activities before and after 6 months of treatment with interferon-b showed a signi®cant negative correlation with D plasma triglycerides. In addition, the change in HL 11 activity after treatment with interferon-b showed a signi®cant positive correlation with D histological activity index in all 13 patients evaluated (r 753, P < 0.01).
DISCUSSION
Among their multiple systemic effects, interferons have been found to in¯uence lipid and lipoprotein metabolism. 19, 20 Taking into account that lipoprotein lipase and hepatic lipase are two key enzymes in the metabolism and interconversion of lipoproteinsÐas demonstrated by the major derangements of lipoproteins in individuals with genetic defectsÐlipase activities should be measured in studies of the effects of diet, drugs or other factors on lipoprotein metabolism. 21 In this prospective study a 6-month course of interferon-b in normolipemic patients with chronic hepatitis C was associated with disturbances in plasma lipoprotein metabolism as de®ned by a signi®cant increase in total, VLDL and LDL triglycerides as well as a tendency for HDL cholesterol levels to decrease. These changes paralleled a marked inhibition in lipoprotein lipase (but not in hepatic lipase) activity. Because no other confounding factors such as diabetes, liver function deterioration, changes in body mass index or concurrent therapy with other drugs were present during the trial, the lipid alterations were probably related to interferon-b. We did not include hyperlipaemic patients because of the potential risk of severe hypertrygliceridaemia and to avoid interferences with lipases assay. We used 6´10 6 U of interferon-b three times a week. However, the optimal dose regimen of interferon-b for chronic hepatitis C has not yet been established. 3, 22 Doses of 9±12´10 6 U three times a week have been reported to be as effective as 6´10 6 U of interferon-a in terms of response to treatment. 23 The effects of interferon-b on lipid metabolism are little known. When administered for 10 days, to patients with stable renal cancer, daily interferon-b serine (a recombinant DNA-derived interferon-b) injections during 9 days produced rapid and dose-dependent increases in plasma triglyceride concentrations of 74% at 4.5 MU, and 136% at 9.0 MU. 24 Furthermore, in this study the reductions in LDL cholesterol of 28% and 50% occurred later than the reductions in triglycerides. In a small study involving patients with chronic hepatitis C, 6 MU of interferon-b daily caused a time-dependent increase in triglycerides during 14 days of therapy. 12 Therefore, the more modest increase in triglyceride concentrations and the absence of reduction in LDL cholesterol observed in our study could be due to the different dose regimen and time-point.
Similar changes have recently been reported in association with interferon-a therapy. 5, 6 Shinohara et al. also tested the activity of post-heparin lipases before and after a short-term course (2 weeks) of high daily doses (9 MU) of interferon-a 2a, and found a decrease in both lipoprotein lipase and hepatic lipase activities. 5 The mechanism(s) for such interferon-b-induced disturbances in lipoprotein metabolism are unclear. A variety of cytokines, including TNF 12 -a, interleukin-1, interferon-a and interferon-c, inhibit lipoprotein lipase activity in post-heparin plasma, adipose tissue, or both, and these cytokines and interferon-b inhibit adipose tissue lipogenesis. 25±28 The reduced lipoprotein lipase activity found in our study might be associated with a lesser availability rather than an inhibition of the released enzyme into plasma. Indeed, some studies indicate that cytokines down-regulate mRNA of lipoprotein lipase. 29 Measurement of lipoprotein lipase mass in addition to lipoprotein lipase activity may con®rm this view. The inhibition of lipoprotein lipase activity is consistent with the major changes in lipoproteins observed in our study, since lipoprotein lipase is thought to be necessary for the clearance of VLDL, which transfers surface constituents to HDL particles, enhancing HDL cholesterol. 30 In fact, the negative correlation between D lipoprotein lipase activity and D plasma tryglycerides supports an interferon-b-induced impairment in the lipolytic pathway. In addition, the enrichment in LDL triglycerides could be ascribed to impaired cholesterol ester transfer protein or lecithin cholesterol acyltransferase activities. 31 Reduced lecithin cholesterol acyltransferase activity is seen in cholestatic syndromes and/or in hepatic failure. 32 Because no patient in our study had evidence of worsening liver function or cholestasis, this mechanism is unlikely. Cholesterol ester transfer protein de®ciency in humans may also result in triglyceride-rich LDL. 33 A decrease in cholesterol ester transfer protein activity and mass was recently demonstrated in patients with chronic hepatitis C during treatment with interferon-a. 5 Nevertheless, interferonb, by inhibiting the activity of lipoprotein lipase, could also have an effect on cholesterol ester transfer protein activity, since adequate activity of lipoprotein lipase enhances the ability of cholesterol ester transfer protein to bind triglyceride-rich substrates such as VLDL. 34 On the other hand, an interferon-b-induced increase in lipogenesis and VLDL secretion in the liver is unlikely in our patients, because interferon-b does not stimulate hepatic fatty acid synthesis as do other cytokines, including interferon-a, TNF-a and interleukin-1. 35 We found no differences in lipoprotein pro®le between patients strati®ed into responders and non-responders to interferon-b, according to accepted criteria of response to treatment, and this has also been observed with interferon-a. 6 However, liver enzyme behaviour correlated with that of lipoprotein lipase, suggesting that the effects of interferon-b on liver in¯ammation paralleled, to some degree, the effects on lipoprotein metabolism. In addition, although in our study hepatic lipase activity was not modi®ed after interferon-b therapyÐin contrast to the effect of interferon-aÐthe signi®cant positive correlation between D HL activity and the improvement in histological lesions in the subset of patients who had a second biopsy also suggests this possibility. 5, 10 In fact, whereas the short-term effects of high daily doses of interferon-a were found to be associated with an inhibition of hepatic lipase activity, the stable hepatic lipase activity after longterm therapy with interferon-b observed in our study might re¯ect less in¯ammatory activity in hepatocytes. 5 No patient in our study had marked increases of serum triglycerides. This is probably due to the fact that we included only patients with normal triglycerides at baseline, since severe hypertriglyceridemia after interferon-a therapy has been reported in relationship to high pre-treatment triglyceride levels and recommendations for monitoring triglyceride levels have been given for this subset of patients. 6±10 We believe that the same policy is reasonable for hypertriglyceridemic patients who are to receive treatment with interferon-b.
